Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimens of Tideglusib vs Placebo in Mild-to-Moderate AD Patients

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimens of Tideglusib vs Placebo in Mild-to-Moderate AD Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tideglusib (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ARGO

    • Most Recent Events

    • 17 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
    • 11 Oct 2012 Results have been reported in a Noscira media release.
    • 11 Oct 2012 Primary endpoint 'Alzheimer's-Disease-Assessment-Scale-cognitive-subpart' has not been met according to a Noscira media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top